PATENT CLAIM ANALYSIS

Application Number: 16040684
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["514", "006200"]

Abstract:
The novel insulin derivates delivers, after administration to humans, insulin as a function of the glucose concentration in the tissue.

Claim (Index 13):
The insulin derivative of  claim 11 , wherein the derivative is:\n B29N \u03f5 -16-(2,3-Difluoro-4-boronobenzoylamino)hexadecanoyl-\u03b3-L-glutamyl desB30 human insulin; B29N \u03f5 -16-(2,3-Difluoro-4-boronobenzoylamino)hexadecanoyl desB30 human insulin; B29N \u03f5 -16-(3-Fluoro-4-boronobenzoylamino)hexadecanoyl desB30 human insulin; B29N \u03f5 -16-(3-Fluoro-4-boronobenzoylamino)hexadecanoyl-\u03b3-L-glutamyl desB30 human insulin; B29N \u03f5 -16-(2,6-Difluoro-4-boronobenzoylamino)hexadecanonyl desB30 human insulin; or B29N \u03f5 -16-(2,3-Difluoro-4-boronobenzoylamino)hexadecanoyl A14E B25H des B30 human insulin.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 95.0
- Lexical Diversity: 1.15
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12935438', '14126215', '13224538', '12673516', '15121206']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8375078911428635
- 35 USC 102 Novelty (BERT): 0.571933456693107
- Combined Prediction Score: 0.8109504476978878
- Mean Citation Score: 445.473044
- Max Citation Score: 501.0652
- Similarity Product: 366.78402373213765

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test